Diabetic Neuropathy Collection: Treatment of Diabetic Neuropathy

Alam, Uazman

doi:10.1007/s13300-020-00784-3

Cited by 2 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,16,42,43 Neuropathic pain in patients with TIND may progressively alleviate in a few weeks or in up to 36 months; 30,41 however, it is necessary to start analgesic therapy to reduce pain. 10,[48][49][50] In some cases, TIND pain is much more severe than that of DN, so singleagent therapy may be maximised, or a second or a third drug may be added to analgesic therapy. 47,51 A poor response to opioids has been observed; 13 however, should pain persist, these drugs could be used additionally to other compounds.…”

Section: Diagnosismentioning

confidence: 99%

“…33 Table 1 shows the drugs used in TIND. 6,20,24,32,[48][49][50]52 Use cautiously in kidney disease and adjust for renal function as needed.…”

Section: Diagnosismentioning

confidence: 99%

“…Neuropathic pain in patients with TIND may progressively alleviate in a few weeks or in up to 36 months; 30,41 however, it is necessary to start analgesic therapy to reduce pain 10,48–50 …”

Section: Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Treatment‐induced neuropathy of diabetes: an update

Quiroz‐Aldave,

Concepción‐Zavaleta,

del Carmen Durand‐Vásquez

et al. 2023

Practical Diabetes

View full text Add to dashboard Cite

Background and aims: Treatment‐induced neuropathy of diabetes is an acute small‐fibre neuropathy associated with rapid glycaemia improvement.Methods: This study is a narrative review carried out based on a bibliographic review, using articles indexed in PubMed/Medline and Scielo.Results: This entity is more frequent in adult patients with poor previous glycaemic control. Its precise pathophysiology is unknown, but it is likely related to unrestored microcirculation changes that occurred during the hyperglycaemic period. It presents with intense, sudden neuropathic pain and autonomic dysfunction after a rapid glycaemic correction and a poorer analgesic response than in diabetic neuropathy.Conclusions: Since rapid glycaemia correction is the cause of this problem, clinical practice guidelines that can help physicians to prevent, diagnose and manage this entity should be developed. Copyright © 2023 John Wiley & Sons.

show abstract

Section: Diagnosismentioning

confidence: 99%

“…33 Table 1 shows the drugs used in TIND. 6,20,24,32,[48][49][50]52 Use cautiously in kidney disease and adjust for renal function as needed.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Treatment‐induced neuropathy of diabetes: an update

Quiroz‐Aldave,

Concepción‐Zavaleta,

del Carmen Durand‐Vásquez

et al. 2023

Practical Diabetes

View full text Add to dashboard Cite

show abstract

“…The major cause of DM is peripheral nervous system (PNS) damage, a common type of nerve damage of the bilateral and symmetric nerves of the feet. The distal to proximal gradient of severity is known as stocking glove neuropathy, which is called DNP ( Alam, 2020 ; Papanas, 2020 ). DNP is primarily a disorder of sensory nerves.…”

Section: Introductionmentioning

confidence: 99%

New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors

et al. 2022

View full text Add to dashboard Cite

Pre-diabetes and diabetes are growing threats to the modern world. Diabetes mellitus (DM) is associated with comorbidities such as hypertension (83.40%), obesity (90.49%), and dyslipidemia (93.43%), creating a substantial burden on patients and society. Reductive and oxidative (Redox) stress level imbalance and inflammation play an important role in DM progression. Various therapeutics have been investigated to treat these neuronal complications. Melatonin and dipeptidyl peptidase IV inhibitors (DPP-4i) are known to possess powerful antioxidant and anti-inflammatory properties and have garnered significant attention in the recent years. In this present review article, we have reviewed the recently published reports on the therapeutic efficiency of melatonin and DPP-4i in the treatment of DM. We summarized the efficacy of melatonin and DPP-4i in DM and associated complications of diabetic neuropathy (DNP) and neuropathic pain. Furthermore, we discussed the mechanisms of action and their efficacy in the alleviation of oxidative stress in DM.

show abstract

Diabetic Neuropathy Collection: Treatment of Diabetic Neuropathy

Cited by 2 publications

References 31 publications

Treatment‐induced neuropathy of diabetes: an update

Treatment‐induced neuropathy of diabetes: an update

New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors

Contact Info

Product

Resources

About